Psychopharmacology

, Volume 215, Issue 3, pp 505–512 | Cite as

Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews

  • Erin M. Rock
  • Jennifer M. Goodwin
  • Cheryl L. Limebeer
  • Aviva Breuer
  • Roger G. Pertwee
  • Raphael Mechoulam
  • Linda A. Parker
Original Investigation

Abstract

Rationale

The interaction between two non-psychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG), which have been reported to act as a 5-hydroxytryptamine 1A (5-HT1A) agonist and antagonist, respectively, was evaluated.

Objective

To evaluate the potential of CBG to reverse the anti-nausea, anti-emetic effects of CBD.

Materials and methods

In experiment 1, rats were pre-treated with CBG (0.0, 1, 5, and 10 mg/kg, ip), 15 min prior to being treated with CBD (experiment 1a: VEH or 5 mg/kg, ip) or 8-OH-DPAT (experiment 1b: VEH or 0.01 mg/kg, ip). Thirty minutes later, all rats received a pairing of 0.1% saccharin solution and LiCl (20 ml/kg of 0.15 M, ip). Seventy-two hours later, the rats received a drug-free taste reactivity test with saccharin to evaluate the effects of the treatments on the establishment of conditioned gaping reactions (a model of nausea). As well, conditioned saccharin avoidance was measured. In experiment 2, Suncus murinus were injected with CBG (5 mg/kg, ip) or VEH 15 min prior to CBD (5 mg/kg) or VEH and 30 min later were injected with LiCl (60 ml/kg of 0.15 M, i.p.), and the number of vomiting episodes were measured.

Results

CBD (5 mg/kg) suppressed conditioned gaping in rats and vomiting in shrews, which were reversed by pre-treatment with all doses of CBG. CBG also prevented the anti-nausea effects of 8-OH-DPAT.

Conclusions

Interactions between moderate doses of CBG and CBD may oppose one another at the 5-HT1A receptor in the regulation of nausea and vomiting.

Keywords

Nausea Vomiting Cannabinoids Cannabigerol Cannabidiol Serotonin 5-HT1A Phytocannabinoid 

Notes

Acknowledgements

The following research was supported by research grants from the Natural Sciences and Engineering Research Council (NSERC) of Canada to LAP, a scholarship from NSERC to EMR, and a grant from NIDA (9789) to RM and RGP. For reprints please contact parkerl@uoguelph.ca.

References

  1. Abrahamov A, Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56:2097–2102PubMedCrossRefGoogle Scholar
  2. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Starvi M et al (2008) Antibacterial cannabinoids from Cannabis sativa: a structure–activity study. J Nat Prod 71:1427–1430PubMedCrossRefGoogle Scholar
  3. Breslin PAS, Grill HJ, Spector AC (1992) A quantitative comparison of taste reactivity behaviors to sucrose before and after lithium chloride pairings: a unidimensional account of palatability. Behav Neurosci 106:820–836PubMedCrossRefGoogle Scholar
  4. Cascio MG, Gauson LA, Ross RA, Pertwee RG (2010) Evidence that the plant cannabionoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 159:129–141PubMedCrossRefGoogle Scholar
  5. Colasanti BK (1990) A comparison of the ocular and central effects of delta-9-tetrahydrocannabinol and cannabigerol. J Ocular Pharmacol Ther 6:259–269CrossRefGoogle Scholar
  6. Colasanti BK, Craig CR, Allara RD (1984) Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol and cannabigerol. Exper Eye Res 39:251–259CrossRefGoogle Scholar
  7. Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptor in the least shrew. Pharmacol Biochem Behav 69:239–249PubMedCrossRefGoogle Scholar
  8. Darmani NA, Janoyan JJ, Crim J, Ramirez J (2007) Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur J Pharmacol 563:187–196PubMedCrossRefGoogle Scholar
  9. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P et al (2008) Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and malastatin type-8. J Pharmacol Exp Ther 325:1007–1015PubMedCrossRefGoogle Scholar
  10. Eisohly HN, Turner CE, Clark AM, Eisohly MA (2006) Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J Pharm Sci 71:1319–1323CrossRefGoogle Scholar
  11. Gaoni Y, Mechoulam R (1964a) Isolation, structure, and partial synthesis of an active component of hashish. J Amer Chem Soc 86:1646–1647CrossRefGoogle Scholar
  12. Gaoni Y, Mechoulam R (1964b) The structure and synthesis of cannabigerol, a new hashish constituent. Proc Chem Soc 82Google Scholar
  13. Grill HC, Norgren R (1978) The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 143:263–279PubMedCrossRefGoogle Scholar
  14. Hayakawa K, Mishima K, Abe K, Hasebe N, Takamatsu F, Yasuda H et al (2004) Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. NeuroReport 15:2381–2385PubMedCrossRefGoogle Scholar
  15. Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacol 174:254–259Google Scholar
  16. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L et al (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318:1375–1387PubMedCrossRefGoogle Scholar
  17. Limebeer CL, Parker LA (1999) Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea. NeuroReport 10:3769–3772PubMedCrossRefGoogle Scholar
  18. Limebeer CL, Parker LA (2003) The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacol 166:120–126Google Scholar
  19. Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, Parker LA (2010) Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharm (in press)Google Scholar
  20. Lucot JB, Crampton GH (1988) 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin, or xylazine. Pharmacol Biochem Behav 33:627–632CrossRefGoogle Scholar
  21. Maor Y, Morowitz M, Gallily R, Mechoulam R (2005) Cannabigerol-dimethyl heptyl (CBG-DMH), a synthetic cannabinoid with hypotensive and vasorelaxant properties. Presented at the symposium of the International Cannabinoid Research Society, Clearwater, FL, JuneGoogle Scholar
  22. Mechoulam R (1970) Marihuana chemistry. Science 168:1159–1163PubMedCrossRefGoogle Scholar
  23. Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S–19SPubMedGoogle Scholar
  24. Mechoulam R, Peters M, Murillo-Rodriquez E, Hanus LO (2007) Cannabidiol—recent advances. Chem Biodiv 4:1678–1692CrossRefGoogle Scholar
  25. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA (2010) Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993–2008. J Forensic Sci 55:1209–1217PubMedCrossRefGoogle Scholar
  26. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K et al (2005) Cannabidiol prevents infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36:1071–1076CrossRefGoogle Scholar
  27. Orr LE, McKernan JF, Bloome B (1980) Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 140:1431–1433PubMedCrossRefGoogle Scholar
  28. Parker LA, Limebeer CL (2008) Cannabinoids and the management of nausea and vomiting. In: Kofalvi A (ed) Cannabinoids and the brain. Springer, New YorkGoogle Scholar
  29. Parker LA, Mechoulam R (2003) Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Phsyiol Behav Sci 38:133–145CrossRefGoogle Scholar
  30. Parker LA, Mechoulam R, Schlievert C (2002) Cannabidiol, a non-psychoactive component of cannabis, and its dimethylheptyl homolog suppress nausea in an experimental model with rats. NeuroReport 13:567–570PubMedCrossRefGoogle Scholar
  31. Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P (2003) Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacol 166:156–162Google Scholar
  32. Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus. Psychopharmacol 171:156–161CrossRefGoogle Scholar
  33. Parker LA, Limebeer CL, Kwiatkowska M (2005) Cannabinoids: effects on vomiting and nausea in animal models. In: Mechoulam R (ed) Cannabinoids as therapeutics. Birkhäuser, Switzerland, pp 183–200CrossRefGoogle Scholar
  34. Parker LA, Kwiatkowska M, Mechoulam R (2006) Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87:61–71CrossRefGoogle Scholar
  35. Parker LA, Limebeer CL, Rana SA (2008) Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. Can J Exp Psychol 62:189–209Google Scholar
  36. Parker, LA., Limebeer CL, Rock EM, Litt DL, Kwiatkowska M., and Piomelli D. (2009) The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine- induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav 97: 121-124Google Scholar
  37. Pertwee RG (2004) In: DiMarzo V (ed) The pharmacology and therapeutic potential of cannabidiol, in cannabinoids. Kluwer, New YorkGoogle Scholar
  38. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008) The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacol 196:389–395CrossRefGoogle Scholar
  39. Rock EM, Limebeer CL, Fletcher PJ, Mechoulam R, Parker LA (2010). Cannabidiol (the non-psychoactive component of cannabis) may act as a 5-HT1A auto-receptor agonist to reduce toxin-induced nausea and vomiting. Poster presented at the Society for Neuroscience meeting, San Diego, CAGoogle Scholar
  40. Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem Res 30:1037–1043PubMedCrossRefGoogle Scholar
  41. Sallan SE, Zinberg NE, Frei E (1975) Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New Engl J Med 293:795–797PubMedCrossRefGoogle Scholar
  42. Tramer MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:1–8CrossRefGoogle Scholar
  43. Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS et al (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterol 121:767–774CrossRefGoogle Scholar
  44. Wilkinson JD, Williamson EM (2007) Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 45:87–92PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Erin M. Rock
    • 1
  • Jennifer M. Goodwin
    • 1
  • Cheryl L. Limebeer
    • 1
  • Aviva Breuer
    • 2
  • Roger G. Pertwee
    • 3
  • Raphael Mechoulam
    • 2
  • Linda A. Parker
    • 1
    • 4
  1. 1.Department of PsychologyUniversity of GuelphGuelphCanada
  2. 2.Institute of Drug ResearchHebrew University Medical FacultyJerusalemIsrael
  3. 3.School of Medical SciencesUniversity of AberdeenAberdeenUK
  4. 4.Department of PsychologyUniversity of GuelphGuelphCanada

Personalised recommendations